Gastrointestinal cancer research : GCR最新文献_第6页

Alternate dosing of cetuximab for patients with metastatic colorectal cancer. 西妥昔单抗在转移性结直肠癌患者中的替代剂量。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

Joleen M Hubbard, Steven R Alberts

{"title":"Alternate dosing of cetuximab for patients with metastatic colorectal cancer.","authors":"Joleen M Hubbard, Steven R Alberts","doi":"","DOIUrl":"","url":null,"abstract":"Background: Many chemotherapeutic regimens used to treat colorectal cancer (CRC), including 5-fluorouracil plus leucovorin in combination with irinotecan (FOLFIRI) or oxaliplatin (FOLFOX), are administered on an every-other-week (q2w) dosing schedule. Chemotherapy in combination with a monoclonal antibody (mAb) directed toward the epidermal growth factor receptor (EGFR) has emerged as an effective treatment option. There are currently 2 anti-EGFR mAbs approved by the United States Food and Drug Administration: cetuximab and panitumumab. Mutations of KRAS, a downstream protein in the EGFR pathway, predict resistance to EGFR mAbs. Thus, cetuximab and panitumumab are indicated for patients without a KRAS mutation (KRAS wild-type). Whereas panitumumab is approved on a q2w dosing schedule, cetuximab is approved as a weekly dose. However, only cetuximab is approved with FOLFIRI for frontline metastatic CRC, whereas panitumumab is approved for third-line. Because concomitant therapies are often administered q2w, the weekly dosing of cetuximab results in additional medical office visits.Design: Several studies have assessed the safety and efficacy of cetuximab q2w. For this review, a comprehensive literature search of studies evaluating cetuximab q2w dosing was conducted. Safety and efficacy results of these trials and retrospective analyses were summarized and reviewed.Results: In general, results with cetuximab q2w were comparable to those obtained with the weekly regimen.Conclusion: These data suggest that for patients for whom weekly treatment with cetuximab presents a substantial burden to their quality of life, q2w dosing of cetuximab is a viable treatment option with a benefit:risk profile similar to that of the weekly regimen.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 2","pages":"47-55"},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674463/pdf/gcr47.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic appendiceal carcinoma diagnosed in an asymptomatic patient with incidental thyroid mass on routine examination. 转移性阑尾癌的诊断无症状的病人附带甲状腺肿块的常规检查。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

Sharan Prakash Sharma, Lewis M Attas

引用次数: 0

Cutaneous metastasis of pancreatic adenocarcinoma as a first clinical manifestation: a case report and review of the literature. 胰腺腺癌皮肤转移为第一临床表现:1例报告及文献复习。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

Kassem Bdeiri, Francois G Kamar

引用次数: 0

Upcoming articles. 即将到来的文章。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

引用次数: 0

Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. 调强放射治疗与三维适形放射治疗肛管鳞状细胞癌的比较。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

Michael D Chuong, Jessica M Freilich, Sarah E Hoffe, William Fulp, Jill M Weber, Khaldoun Almhanna, William Dinwoodie, Nikhil Rao, Kenneth L Meredith, Ravi Shridhar

{"title":"Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal.","authors":"Michael D Chuong, Jessica M Freilich, Sarah E Hoffe, William Fulp, Jill M Weber, Khaldoun Almhanna, William Dinwoodie, Nikhil Rao, Kenneth L Meredith, Ravi Shridhar","doi":"","DOIUrl":"","url":null,"abstract":"Purpose: We compared our institutional experience using 3D conformal radiation therapy (3DCRT) vs. IMRT (intensity-modulated radiation therapy) for anal cancer.Methods: We performed a single-institution retrospective review of all patients with squamous cell carcinoma anal cancer treated from September 2000 through September 2011, using definitive chemoradiation with curative intent.Results: This study included 89 consecutive patients (37 3DCRT, 52 IMRT). Median follow-up for all patients, IMRT patients alone, and CRT patients alone was 26.5 months (range, 3.5-133.6), 20 months (range, 3.5-125.5), and 61.9 months (range, 7.6-133.6), respectively. Three-year overall survival (OS), progression-free survival (PFS), locoregional control (LRC), and colostomy-free survival (CFS) were 91.1%, 82.3%, 90.8%, and 91.3% in the IMRT cohort and 86.1%, 72.5%, 91.9%, and 93.7% in the 3DCRT group (all P > .1). More patients in the 3DCRT group required a treatment break (11 vs. 4; P = .006), although the difference in median treatment break duration was not significant (12.2 vs. 8.0 days; P = .35). Survival did not differ based on whether a treatment break was needed (all P > .1). Acute grade ≥3 nonhematologic toxicity was decreased in the IMRT cohort (21.1 vs. 59.5%; P < .0001). Acute grade ≥3 skin toxicity was worse in the 3DCRT group (P < .0001), whereas an improvement in late grade ≥3 gastrointestinal (GI) toxicity was observed in the IMRT patients (P = .012).Conclusions: This study is the largest thus far to compare 3DCRT and IMRT for definitive treatment of anal cancer. Although long-term outcomes did not significantly differ based on RT technique, a marked decrease in adverse effects and the need for a treatment break was achieved with IMRT.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"6 2","pages":"39-45"},"PeriodicalIF":0.0,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674462/pdf/gcr39.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31489295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tenth Annual ISGIO Meeting. ISGIO第十届年会。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

David H Ilson

引用次数: 0

Management of a patient diagnosed with pancreatic cancer and myelodysplastic syndrome. 诊断为胰腺癌和骨髓增生异常综合征患者的处理。

Gastrointestinal cancer research : GCR Pub Date : 2013-03-01

Elizabeth Won, Kenneth H Yu, Ali Shamseddine, Leonard Saltz, Deborah Mukherjee, Ali Haydar, Ashwaq El-Olayan, Sally Temraz, Mohamed Naghy, Dorothy Makanjoula, Eileen M O'Reilly, Ghassan K Abou-Alfa

引用次数: 0

Characteristics and outcomes of adenosquamous carcinoma of the pancreas. 胰腺腺鳞癌的特点和预后。

Gastrointestinal cancer research : GCR Pub Date : 2013-02-01 DOI: 10.1200/JCO.2013.31.4_SUPPL.311

C. Simone, Tania Zuluaga Toro, E. Chan, Michael M. Feely, J. Trevino, T. George

{"title":"Characteristics and outcomes of adenosquamous carcinoma of the pancreas.","authors":"C. Simone, Tania Zuluaga Toro, E. Chan, Michael M. Feely, J. Trevino, T. George","doi":"10.1200/JCO.2013.31.4_SUPPL.311","DOIUrl":"https://doi.org/10.1200/JCO.2013.31.4_SUPPL.311","url":null,"abstract":"BACKGROUND\u0000Adenosquamous carcinoma of the pancreas (ASCAP) is a rare histologic type of pancreatic carcinoma that constitutes 1% to 4% of all pancreatic exocrine malignancies. It has a clinical presentation similar to that of adenocarcinoma of the pancreas (ACP), but may have a worse overall prognosis, with most patients surviving for less than 2 years.\u0000\u0000\u0000METHODS\u0000This was an institutional, retrospective, cohort analysis of 237 patients who underwent resection of pancreatic cancer with curative intent.\u0000\u0000\u0000RESULTS\u0000Of the 237 cases examined, we identified 7 (2.9%) with histologically confirmed ASCAP. Demographics, comorbidities, risk factors, presenting symptoms, survival data, tumor characteristics, and types of treatment for each patient were included in the analysis. Risk factors for development of ASCAP were not conclusive. Although human papilloma virus (HPV) has been implicated in other squamous cell cancers, in our cohort, its involvement in ASCAP was 0%. Presurgical fine-needle aspiration failed to identify the invasive squamous cell component in all cases. In this cohort analysis, overall survival ranged from 3 to 25 months, with 2 patients surviving more than 20 months after surgical resection. With a median follow-up of 2.9 years, our data demonstrate a trend to worse median overall survival for ASCAP than for ACP (8.2 vs. 20.4 months; P = .23), with a limited number of long-term survivors.\u0000\u0000\u0000CONCLUSIONS\u0000Although recommended, adjuvant treatment was inconsistently provided for patients in this ASCAP cohort. Published data show variability in overall survival, but our findings support that surgical resection is one of the few options for control of this rare, poorly understood pancreatic malignancy. Further research is necessary to define risk factors and adjuvant and neoadjuvant treatments, to help improve patient outcomes.","PeriodicalId":12695,"journal":{"name":"Gastrointestinal cancer research : GCR","volume":"44 1","pages":"75-9"},"PeriodicalIF":0.0,"publicationDate":"2013-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81343206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 47

A young woman with liver cancer. 一个患肝癌的年轻女子。

Gastrointestinal cancer research : GCR Pub Date : 2013-01-01

Celina S Ang, Richard K Do, Ali Shamseddine, Eileen M O'Reilly, Ali Haydar, Ashwaq Al-Olayan, Walid Faraj, Fouad Boulos, Mohamed Naghy, Dorothy Makanjoula, Hassan Farran, Hassan Sibai, David Wehbe, David P Kelsen, Ghassan K Abou-Alfa

引用次数: 0

CME Post-Test. 芝加哥商品交易所测试后。

Gastrointestinal cancer research : GCR Pub Date : 2013-01-01 DOI: 10.1097/01720610-200709000-00005

引用次数: 0